Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04184674
Other study ID # APHP191033
Secondary ID 2019-A02814-53
Status Completed
Phase N/A
First received
Last updated
Start date June 11, 2020
Est. completion date June 11, 2022

Study information

Verified date February 2024
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pulmonary distension induced by mechanical ventilation physiologically alters right ventricle pre and after-load, hence might lead to right ventricle failure. The hypothesis is that in Acute Respiratory Distress Syndrome, the occurence of a right ventricle failure under lung protective ventilation might : i) be correlated to the transpulmonary pressure level, ii) lead to global heart failure, iii) and extremely result in poor outcome and death. The primary objective is to test the impact of transpulmonary pressure on right ventricular function in Acute Respiratory Distress Syndrome in adults and children. Secondary objectives are : i) to compare thresholds of transpulmonary pressure associated with right ventricle failure between children and adults. ii) to assess if there is an association between transpulmonary pressure and morbidity and mortality. - For pediatric patients, a specific monitoring with electrical impedance tomography (EIT) will allow: - To assess if the transpulmonary pressure is associated with the level of regional pulmonary overdistention (or collapse) on electrical impedance tomography.(EIT) - To assess if there is an association between the occurrence of right ventricular failure, and distribution of ventilation on EIT.


Description:

Acute Respiratory Distress Syndrome (ARDS) is an acute inflammatory lung injury associated with a high pulmonary vascular permeability, leading to acute respiratory failure. Positive pressure mechanical ventilation,improves survival but might lead to ventilator-induced lung injury (VILI) and right ventricular failure. This hemodynamic effect is more important when compliance is decreased, especially in ARDS. The use of long protective ventilation (with low tidal volumes and low plateau pressures) has improved prognosis of ARDS in adult patients. However, tidal volume and plateau pressures do not always reflect the lung deformation and the stress induced by the ventilation; these variables depend on the characteristics of the patient's respiratory system. Therefore, management focuses on ventilation strategies according to these characteristics. Among tools used to evaluate respiratory physiological parameters, the esophageal pressure measurement is easily feasible at the bedside, and well estimates pleural pressure and pulmonary distension. During invasive ventilation, transpulmonary pressure (PL) can be obtained with the difference between the airway pressure and the esophageal pressure. Calculation of transpulmonary pressure in ARDS allows optimal ventilator management of adult and children treated for ARDS. Although individualized ventilation techniques have shown some benefits in ARDS, studies have failed to show that survival could be improved by such strategies. This lack of efficacy could be partly explained by the hemodynamic impact of ventilation-induced pulmonary distension. It therefore seems essential to combine a robust assessment of right ventricular function with measurements of transpulmonary pressure in order to know the real hemodynamic impact of positive pressure ventilation in ARDS in adults and children. The primary objective is to test the impact of transpulmonary pressure on right ventricular functionin ARDS adults and children. Secondary objectives are : i) to compare thresholds of transpulmonary pressure associated to right ventricle failure between children and adults ii) to assess if there is an association between transpulmonary pressure and morbidity and mortality. - For pediatric patients, a specific monitoring with electrical impedance tomography (EIT) will allow: - To assess if the transpulmonary pressure is associated with the level of regional pulmonary overdistention (or collapse) on electrical impedance tomography.(EIT) - To assess if there is an association between the occurrence of right ventricular failure, and distribution of ventilation on EIT.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date June 11, 2022
Est. primary completion date June 11, 2022
Accepts healthy volunteers No
Gender All
Age group 1 Month and older
Eligibility Inclusion Criteria: - Patients over one month - Patients with mild to severe ARDS (onset within 48 hours). ARDS definition will follow Berlin guidelines for adults, and Pediatric Acute Lung Injury Consensus Conference (PALICC) guidelines for children - Signed consent Exclusion Criteria : - Neonates less than 28 days-old - Pregnancy or breastfeeding - Any contra-indication to esophageal manometry (less than one month esophagus surgery, bronchopleural or esotracheal fistula, latex allergy) - No social care

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Pneumotachograph
Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management : The first measurement will be performed 5 minutes after the initial ventilator settings. Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution. An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures).
Esophageal catheter
Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management The first measurement will be performed 5 minutes after the initial ventilator settings. Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution. An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures).
Transthoracic and / or transesophageal cardiac ultrasound
The right ventricle systolic function will be assessed thanks to a transthoracic cardiac ultrasound in children, and a transthoracic of a transesophageal cardiac ultrasound in adults : Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management : The first measurement will be performed 5 minutes after the initial ventilator settings. Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution. An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures).
Electrical impedance tomography (EIT) for pediatric patients
For pediatric patients: measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management.

Locations

Country Name City State
France Hôpital Ambroise Paré Boulogne-Billancourt
France Hôpital Necker-Enfants Malades Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Right ventricle failure Right ventricle failure is defined, by ultrasound, as a composite criteria associating :
end-diastolic right ventricle/left ventricle area ratio > 0.6 and/or Acute Cor Pulmonale (assocation with a septal dyskinesia),
and/or a tricuspid annular plane systolic excursion < 1,6 cm (adults), z-score < -2 (children),
and/or a doppler-derived tricuspid lateral annular systolic velocity (S wave) < 10 cm/s,
and/or a two-dimensional Fractional Area Change (defined as end-diastolic area - end-systolic area)/end-diastolic area x100) < 35%,
and/or a peak right ventricle free wall 2D strain < -30% (adults), z-score < 2 (children).
Three days
Secondary Airways pressure Airways pressure (Paw) will be measured in cmH2O thanks to a pneumotachograph connected to the ventilator. Three days
Secondary Oesophageal pressure Esophageal pressure (Pes) will be measured in cmH2O thanks to an oesophageal balloon catheter introduced in the mid-esophagus of the patient and connected to a manometer. Three days
Secondary Transpulmonary pressure calculation Measurements will be performed at different moments during the respiratory cycle: after an inspiratory pause to evaluate the tele-inspiratory transpulmonary pressure (PL-insp), and after an expiratory pause to evaluate the tele-expiratory transpulmonary pressure (PL-PEP ). The PL-insp will be calculated using the ratio between the elastance of the chest wall (Ecw) and of the respiratory system (Ers) thanks to this formula PL = Paw - Paw x (Ecw/Ers). The PL-exp will be calculated using the ratio between Paw et Pes (PL = Paw - Pes). Transpulmonary pressure will be expressed in cmH2O. Three days
Secondary Vaso-Active Inotrope Score (VIS) Correlation between transpulmonary pressure and morbidity. Vaso-Active Inotrope Score is a hemodynamic score taking into account the cumulative doses of inotropic or vassopressive drugs. It is obtained thanks this calculation : VIS = dopamine dose (µg/kg/min) + dobutamine dose (µg/kg/min) + 100 x epinephrine dose (µg/kg/min) + 10 x milrinone dose (µg/kg/min) + 10000 x vasopressin dose (µg/kg/min) + 100 x norepinephrine dose (µg/kg/min). Its value ranges from zero, which is associated to a better outcome, to the maximum cumulative dose without any limit. Three days
Secondary Duration of treatment with vasoactive or inotropic drugs Number of days under vaso-active or inotropic drugs 3 months after hospitalization in Intensive Care Unit
Secondary Pediatric logistic organ dysfunction score Pediatric logistic organ dysfunction score is a specific pediatric multiple organ dysfunction score that includes 10 variables corresponding to 5 organ dysfunctions. Values extend from 0 (best outcome) to 33 (worst outcome). Three days
Secondary Sepsis-related Organ Function Assessement score Sepsis-related Organ Function Assessement score is a multiple organ dysfunction score that includes several variables corresponding to 6 organ dysfunctions. Values extend from 0 (best outcome) to 24 (worst outcome). Three days
Secondary Invasive and non invasive ventilation free days Number of invasive and non invasive ventilation free days 3 months after hospitalization in Intensive Care Unit
Secondary Lung and Chest Wall compliance Lung and chest wall compliances (in mL/cmH2O) will be calculated thanks to the respective ratios tidal volume/(PL-insp - PL-PEP) and tidal volume/(Pes insp - Pes-PEP). Three days
Secondary Length of hospitalization Length of hospitalization in Intensive Care Unit and in hospital in days. 3 months after hospitalization in Intensive Care Unit
Secondary Mortality at 28 days Death in Intensive Care Unit and at 28 days of hospitalization. 28 days
Secondary Mortality in Intensive Care Unit Death in Intensive Care Unit. 3 months after hospitalization in Intensive Care Unit
Secondary Eletrical impedance tomography Electrical impedance tomography will be monitored only in children. Several methods will be used and compared, based on e.g. pixel information of lung aeration, to assess end-expiratory lung volume (ELLV, in mL) and the distribution of ventilation 3 days
See also
  Status Clinical Trial Phase
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Recruiting NCT05535543 - Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
Completed NCT04695392 - Restore Resilience in Critically Ill Children N/A
Terminated NCT04972318 - Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia N/A
Completed NCT04534569 - Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
Completed NCT04078984 - Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
Completed NCT04451291 - Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure N/A
Not yet recruiting NCT06254313 - The Role of Cxcr4Hi neutrOPhils in InflueNza
Not yet recruiting NCT04798716 - The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 Phase 1/Phase 2
Withdrawn NCT04909879 - Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome Phase 2
Terminated NCT02867228 - Noninvasive Estimation of Work of Breathing N/A
Not yet recruiting NCT02881385 - Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation N/A
Completed NCT02545621 - A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
Completed NCT02232841 - Electrical Impedance Imaging of Patients on Mechanical Ventilation N/A
Withdrawn NCT02253667 - Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients N/A
Completed NCT01504893 - Very Low Tidal Volume vs Conventional Ventilatory Strategy for One-lung Ventilation in Thoracic Anesthesia N/A
Completed NCT02889770 - Dead Space Monitoring With Volumetric Capnography in ARDS Patients N/A
Withdrawn NCT01927237 - Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide N/A
Completed NCT01680783 - Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure N/A
Completed NCT02814994 - Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients N/A